The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis
Open accessAbstract
The epithelial-to-mesenchymal transition (EMT) is a crucial program for the invasion and metastasis of epithelial tumors that involves loss of cell–cell adhesion and increased cell mobility; however, mechanisms underlying this transition are not fully elucidated. Here, we propose a novel mechanism through which the nicotinamide adenine dinucleotide-dependent histone deacetylase SIRT1 regulates EMT in prostate cancer cells through cooperation with the EMT inducing transcription factor ZEB1. We found that forced expression of SIRT1 in non-transformed PZ-HPV-7 prostate epithelial cells disrupts the epithelial morphology concomitant with decreased expression of the epithelial marker, E-cadherin, and increased expression of mesenchymal markers. In contrast, silencing SIRT1 in metastatic prostate tumor cells restores cell–cell adhesion and induces a shift toward an epithelial morphology concomitant with increased expression of E-cadherin and decreased expression of mesenchymal markers. We also found that SIRT1 has a physiologically relevant role in endogenous EMT induced by EGF signaling in prostate cancer cells. We propose that the regulation of EMT by SIRT1 involves modulation of, and cooperation with, the EMT inducing transcription factor ZEB1. Specifically, we show that SIRT1 silencing reduces expression of ZEB1 and that SIRT1 is recruited to the E-cadherin proximal promoter by ZEB1 to deacetylate histone H3 and to reduce binding of RNA polymerase II, ultimately suppressing E-cadherin transcription. We thus identify a necessary role for ZEB1 in SIRT1-mediated EMT. Finally, we show that reduction of SIRT1 decreases prostate cancer cell migration in vitro and metastasis in vivo in immunodeficient mice, which is largely independent of any general effects of SIRT1 on prostate cancer growth and survival. We therefore identify SIRT1 as a positive regulator of EMT and metastatic growth of prostate cancer cells and our findings implicate overexpressed SIRT1 as a potential therapeutic target to reverse EMT and to prevent prostate cancer progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complex networks orchestrate epithelial–mesenchymal transitions
Thiery, J. P., & Sleeman, J. P. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1835 · Cited by 3,958
Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?
Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121
Epithelial–mesenchymal transitions in development and pathologies
Thiery, J. P. (2003) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2003.10.006 · Cited by 1,704
Larue, L., & Bellacosa, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209091 · Cited by 1,228
Calorie restriction, SIRT1 and metabolism: understanding longevity
Bordone, L., & Guarente, L. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1616 · Cited by 1,020
The SLUG zinc-finger protein represses E-cadherin in breast cancer.
Hajra, K. M., Chen, D. Y., & Fearon, E. R. (2002) · PubMed · Cited by 1,020
Eger, A., Aigner, K., Sonderegger, S., Dampier, B., Oehler, S., Schreiber, M., Berx, G., Cano, A., Beug, H., & Foisner, R. (2005) · Oncogene · doi:10.1038/sj.onc.1208429 · Cited by 808
Calorie restriction–the SIR2 connection
Guarente, L., & Picard, F. (2005) · Cell · doi:10.1016/j.cell.2005.01.029 · Cited by 793
Leaving the neighborhood: molecular mechanisms involved during epithelial‐mesenchymal transition
Savagner, P. (2001) · BioEssays · doi:10.1002/bies.1132 · Cited by 679
Voulgari, A., & Pintzas, A. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.03.002 · Cited by 671
Umbas, R., Schalken, J. A., Aalders, T. W., Carter, B. S., Karthaus, H. F. M., Schaafsma, H. E., Debruyne, F. M. J., & Isaacs, W. B. (1992) · PubMed · Cited by 611
Transcriptional regulation of cell polarity in EMT and cancer
Moreno-Bueno, G., Portillo, F., & Cano, A. (2008) · Oncogene · doi:10.1038/onc.2008.346 · Cited by 610
SIRT1 Controls Endothelial Angiogenic Functions During Vascular Growth
Potente, M., Ghaeni, L., Baldessari, D., Mostoslavsky, R., Rossig, L., Dequiedt, F., Haendeler, J., Mione, M., Dejana, E., Alt, F. W., et al. (2007) · Genes & Development · doi:10.1101/gad.435107 · Cited by 608
Transcriptional regulation of cadherins during development and carcinogenesis
Peinado, H., Portillo, F., & Cano, A. (2004) · The International Journal of Developmental Biology · doi:10.1387/ijdb.041794hp · Cited by 561
SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions
Vandewalle, C. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki965 · Cited by 542
Sánchez-Tilló, E., Lázaro, A., Torrent, R., Cuatrecasas, M., Vaquero, E. C., Castells, A., Engel, P., & Postigo, A. (2010) · Oncogene · doi:10.1038/onc.2010.102 · Cited by 504
Sirtuins: critical regulators at the crossroads between cancer and aging
Saunders, L. R., & Verdin, E. (2007) · Oncogene · doi:10.1038/sj.onc.1210616 · Cited by 489
The role of the ZEB family of transcription factors in development and disease
Vandewalle, C., Van Roy, F., & Berx, G. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8465-8 · Cited by 486
Sirtuin Functions in Health and Disease
Yamamoto, H., Schoonjans, K., & Auwerx, J. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0079 · Cited by 480
SIRT1 Is Significantly Elevated in Mouse and Human Prostate Cancer
Huffman, D. M., Grizzle, W. E., Bamman, M. M., Kim, J.-S., Eltoum, I. A., Elgavish, A., & Nagy, T. R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0085 · Cited by 430
Transitions between epithelial and mesenchymal states in development and disease
Baum, B., Settleman, J., & Quinlan, M. P. (2008) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2008.02.001 · Cited by 398
Graham, T. R., Zhau, H. E., Odero-Marah, V. A., Osunkoya, A. O., Kimbro, K. S., Tighiouart, M., Liu, T., Simons, J. W., & O'Regan, R. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2559 · Cited by 384
The Critical Role of the Class III Histone Deacetylase SIRT1 in Cancer
Liu, T., Liu, P. Y., & Marshall, G. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3365 · Cited by 384
Guarente, L. (2007) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2007.72.024 · Cited by 371
The interaction between FOXO and SIRT1: tipping the balance towards survival
Giannakou, M. E., & Partridge, L. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.07.006 · Cited by 354
Eades, G., Yao, Y., Yang, M., Zhang, Y., Chumsri, S., & Zhou, Q. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229401 · Cited by 263
Kwon, H.-S., & Ott, M. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.08.001 · Cited by 229
Richmond, P. J. M., Karayiannakis, A. J., Nagafuchi, A., Kaisary, A. V., & Pignatelli, M. N. (1997) · PubMed · Cited by 226
Tryndyak, V. P., Beland, F. A., & Pogribny, I. P. (2010) · International Journal of Cancer · doi:10.1002/ijc.24972 · Cited by 224
Deacetylation of cortactin by SIRT1 promotes cell migration
Zhang, Y., Zhang, M., Dong, H., Yong, S., Li, X., Olashaw, N., Kruk, P. A., Cheng, J. Q., Bai, W., Chen, J., et al. (2009) · Oncogene · doi:10.1038/onc.2008.388 · Cited by 203
Expression of DBC1 and SIRT1 Is Associated with Poor Prognosis of Gastric Carcinoma
Cha, E. J., Noh, S. J., Kwon, K. S., Kim, C. Y., Park, B.-H., Park, H. S., Lee, H., Chung, M. J., Kang, M. J., Lee, D. G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3329 · Cited by 187
Mimeault, M., & Batra, S. K. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi229 · Cited by 158
Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma
Lee, H., Kim, K. R., Noh, S. J., Park, H. S., Kwon, K. S., Park, B., Jung, S. H., Youn, H. J., Lee, B. K., Chung, M. J., et al. (2010) · Human Pathology · doi:10.1016/j.humpath.2010.05.023 · Cited by 153
Human Sir2 and the ‘silencing’ of p53 activity
Smith, J. S. (2002) · Trends in Cell Biology · doi:10.1016/s0962-8924(02)02342-5 · Cited by 141
Shtutman, M. S., Levina, E. M., Ohouo, P. Y., Baig, M. S., & Roninson, I. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2106 · Cited by 139
SIRT1 Expression is Associated With Poor Prognosis of Diffuse Large B-Cell Lymphoma
Jang, K. Y., Hwang, S. H., Kwon, K. S., Kim, K. R., Choi, H. N., Lee, N., Kwak, J., Park, B., Park, H. S., Chung, M. J., et al. (2008) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31816b6478 · Cited by 122
Wallerand, H., Robert, G., Pasticier, G., Ravaud, A., Ballanger, P., Reiter, R. E., & Ferrière, J.-M. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.12.018 · Cited by 113
Hajra, K. M., Ji, X., & Fearon, E. R. (1999) · Oncogene · doi:10.1038/sj.onc.1203336 · Cited by 112
Dai, Y., Ngo, D., Forman, L. W., Qin, D. C., Jacob, J., & Faller, D. V. (2007) · Molecular Endocrinology · doi:10.1210/me.2006-0467 · Cited by 98
Self-citationDistinct HIC1-SIRT1-p53 Loop Deregulation in Lung Squamous Carcinoma and Adenocarcinoma Patients
Tseng, R., Lee, C.-C., Hsu, H., Tzao, C., & Wang, Y. (2009) · Neoplasia · doi:10.1593/neo.09470 · Cited by 97
SIRT1: roles in aging and cancer
Kim, E.-J., & Um, S. (2008) · BMB Reports · doi:10.5483/bmbrep.2008.41.11.751 · Cited by 92
Transcription Regulation by Class III Histone Deacetylases (HDACs)—Sirtuins
Dai, Y. (2008) · Translational Oncogenomics · doi:10.4137/tog.s483 · Cited by 82
Self-citationEllis-Connell, A. L., Zhenxun, W., Yu, X., & Mertz, J. E. (2010) · Journal of Virology · doi:10.1128/jvi.02706-09 · Cited by 68
Dai, Y., Ngo, D., Jacob, J., Forman, L. W., & Faller, D. V. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn117 · Cited by 65
Self-citationLacher, M. D., Shiina, M., Chang, P. D., Keller, D., Tiirikainen, M., & Korn, W. M. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-91 · Cited by 29
Cited by
Regulatory networks defining EMT during cancer initiation and progression
Craene, B. D., & Berx, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3447 · Cited by 2,487
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,284
Epithelial-Mesenchymal Plasticity in Cancer Progression and Metastasis
Lu, W., & Kang, Y. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.04.010 · Cited by 1,030
Serrano-Gomez, S. J., Maziveyi, M., & Alahari, S. K. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0502-x · Cited by 814
EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness
Sánchez-Tilló, E., Liu, Y., de Barrios, O., Siles, L., Fanlo, L., Cuatrecasas, M., Darling, D. S., Dean, D. C., Castells, A., & Postigo, A. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1122-2 · Cited by 518
Metadata
- Authors
- Byles, V, Zhu, L., Lovaas, J. D., Chmilewski, L. K., Wang, J., Faller, D. V., & Dai, Y.
- Venue
- Oncogene
- Published
- 2012-01-16
- Volume
- 31
- Issue
- 43
- Pages
- 4619-4629
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2010338855
- Cited by
- 309
- References
- 45
- FWCI
- 11.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.